Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Distinct profiles of TERT promoter mutations and telomerase expression in head and neck cancer and cervical carcinoma.

Annunziata C, Pezzuto F, Greggi S, Ionna F, Losito S, Botti G, Buonaguro L, Buonaguro FM, Tornesello ML.

Int J Cancer. 2018 Mar 31. doi: 10.1002/ijc.31412. [Epub ahead of print]

PMID:
29603728
2.

Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.

Lee JM, Nair J, Zimmer A, Lipkowitz S, Annunziata CM, Merino MJ, Swisher EM, Harrell MI, Trepel JB, Lee MJ, Bagheri MH, Botesteanu DA, Steinberg SM, Minasian L, Ekwede I, Kohn EC.

Lancet Oncol. 2018 Feb;19(2):207-215. doi: 10.1016/S1470-2045(18)30009-3. Epub 2018 Jan 18.

PMID:
29361470
3.

Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human Carcinomas.

Fantini M, David JM, Saric O, Dubeykovskiy A, Cui Y, Mavroukakis SA, Bristol A, Annunziata CM, Tsang KY, Arlen PM.

Front Immunol. 2018 Jan 4;8:1899. doi: 10.3389/fimmu.2017.01899. eCollection 2017.

4.

Risk Factors and Predictors of Significant Chondral Surface Change From Primary to Revision Anterior Cruciate Ligament Reconstruction: A MOON and MARS Cohort Study.

MARS Group, Magnussen RA, Borchers JR, Pedroza AD, Huston LJ, Haas AK, Spindler KP, Wright RW, Kaeding CC, Allen CR, Anderson AF, Cooper DE, DeBerardino TM, Dunn WR, Lantz BA, Mann B, Stuart MJ, Albright JP, Amendola A, Andrish JT, Annunziata CC, Arciero RA, Bach BR Jr, Baker CL 3rd, Bartolozzi AR, Baumgarten KM, Bechler JR, Berg JH, Bernas GA, Brockmeier SF, Brophy RH, Bush-Joseph CA, Butler JB 5th, Campbell JD, Carey JL, Carpenter JE, Cole BJ, Cooper JM, Cox CL, Creighton RA, Dahm DL, David TS, Flanigan DC, Frederick RW, Ganley TJ, Garofoli EA, Gatt CJ Jr, Gecha SR, Giffin JR, Hame SL, Hannafin JA, Harner CD, Harris NL Jr, Hechtman KS, Hershman EB, Hoellrich RG, Hosea TM, Johnson DC, Johnson TS, Jones MH, Kamath GV, Klootwyk TE, Levy BA, Ma CB, Maiers GP 2nd, Marx RG, Matava MJ, Mathien GM, McAllister DR, McCarty EC, McCormack RG, Miller BS, Nissen CW, O'Neill DF, Owens BD, Parker RD, Purnell ML, Ramappa AJ, Rauh MA, Rettig AC, Sekiya JK, Shea KG, Sherman OH, Slauterbeck JR, Smith MV, Spang JT, Svoboda SJ, Taft TN, Tenuta JJ, Tingstad EM, Vidal AF, Viskontas DG, White RA, Williams JS Jr, Wolcott ML, Wolf BR, York JJ.

Am J Sports Med. 2018 Mar;46(3):557-564. doi: 10.1177/0363546517741484. Epub 2017 Dec 15.

PMID:
29244532
5.

Clinical trials in gynecologic oncology: Past, present, and future.

Annunziata CM, Kohn EC.

Gynecol Oncol. 2018 Feb;148(2):393-402. doi: 10.1016/j.ygyno.2017.11.026. Epub 2017 Dec 6. Review.

PMID:
29212614
6.

SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors.

Higham CS, Steinberg SM, Dombi E, Perry A, Helman LJ, Schuetze SM, Ludwig JA, Staddon A, Milhem MM, Rushing D, Jones RL, Livingston M, Goldman S, Moertel C, Wagner L, Janhofer D, Annunziata CM, Reinke D, Long L, Viskochil D, Baker L, Widemann BC.

Sarcoma. 2017;2017:8685638. doi: 10.1155/2017/8685638. Epub 2017 Sep 12.

7.

PI3Kδ inhibition causes feedback activation of PI3Kα in the ABC subtype of diffuse large B-cell lymphoma.

Pongas GN, Annunziata CM, Staudt LM.

Oncotarget. 2017 Sep 13;8(47):81794-81802. doi: 10.18632/oncotarget.20864. eCollection 2017 Oct 10.

8.

Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer.

Lee JM, Hays JL, Chiou VL, Annunziata CM, Swisher EM, Harrell MI, Yu M, Gordon N, Sissung TM, Ji J, Figg WD, Minasian L, Lipkowitz S, Wood BJ, Doroshow J, Kohn EC.

Oncotarget. 2017 Mar 25;8(45):79175-79187. doi: 10.18632/oncotarget.16577. eCollection 2017 Oct 3.

9.

NFκB Promotes Ovarian Tumorigenesis via Classical Pathways That Support Proliferative Cancer Cells and Alternative Pathways That Support ALDH+ Cancer Stem-like Cells.

House CD, Jordan E, Hernandez L, Ozaki M, James JM, Kim M, Kruhlak MJ, Batchelor E, Elloumi F, Cam MC, Annunziata CM.

Cancer Res. 2017 Dec 15;77(24):6927-6940. doi: 10.1158/0008-5472.CAN-17-0366. Epub 2017 Oct 26.

PMID:
29074539
10.

BRD4 facilitates DNA damage response and represses CBX5/Heterochromatin protein 1 (HP1).

Pongas G, Kim MK, Min DJ, House CD, Jordan E, Caplen N, Chakka S, Ohiri J, Kruhlak MJ, Annunziata CM.

Oncotarget. 2017 May 3;8(31):51402-51415. doi: 10.18632/oncotarget.17572. eCollection 2017 Aug 1.

11.

Surgical Predictors of Clinical Outcomes After Revision Anterior Cruciate Ligament Reconstruction.

MARS Group, Allen CR, Anderson AF, Cooper DE, DeBerardino TM, Dunn WR, Haas AK, Huston LJ, Lantz BBA, Mann B, Nwosu SK, Spindler KP, Stuart MJ, Wright RW, Albright JP, Amendola AN, Andrish JT, Annunziata CC, Arciero RA, Bach BR Jr, Baker CL 3rd, Bartolozzi AR, Baumgarten KM, Bechler JR, Berg JH, Bernas GA, Brockmeier SF, Brophy RH, Bush-Joseph CA, Butler JB 5th, Campbell JD, Carey JL, Carpenter JE, Cole BJ, Cooper JM, Cox CL, Creighton RA, Dahm DL, David TS, Flanigan DC, Frederick RW, Ganley TJ, Garofoli EA, Gatt CJ Jr, Gecha SR, Giffin JR, Hame SL, Hannafin JA, Harner CD, Harris NL Jr, Hechtman KS, Hershman EB, Hoellrich RG, Hosea TM, Johnson DC, Johnson TS, Jones MH, Kaeding CC, Kamath GV, Klootwyk TE, Levy BA, Ma CB, Maiers GP 2nd, Marx RG, Matava MJ, Mathien GM, McAllister DR, McCarty EC, McCormack RG, Miller BS, Nissen CW, O'Neill DF, Owens BD, Parker RD, Purnell ML, Ramappa AJ, Rauh MA, Rettig AC, Sekiya JK, Shea KG, Sherman OH, Slauterbeck JR, Smith MV, Spang JT, Svoboda SJ, Taft TN, Tenuta JJ, Tingstad EM, Vidal AF, Viskontas DG, White RA, Williams JS Jr, Wolcott ML, Wolf BR, York JJ.

Am J Sports Med. 2017 Sep;45(11):2586-2594. doi: 10.1177/0363546517712952. Epub 2017 Jul 11.

PMID:
28696164
12.

Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers.

Peer CJ, Lee JM, Roth J, Rodgers L, Nguyen J, Annunziata CM, Minasian L, Kohn EC, Figg WD.

Cancer Chemother Pharmacol. 2017 Jul;80(1):165-175. doi: 10.1007/s00280-017-3346-1. Epub 2017 Jun 2.

PMID:
28577239
13.

Subsequent Surgery After Revision Anterior Cruciate Ligament Reconstruction: Rates and Risk Factors From a Multicenter Cohort.

MARS Group, Ding DY, Zhang AL, Allen CR, Anderson AF, Cooper DE, DeBerardino TM, Dunn WR, Haas AK, Huston LJ, Lantz BBA, Mann B, Spindler KP, Stuart MJ, Wright RW, Albright JP, Amendola AN, Andrish JT, Annunziata CC, Arciero RA, Bach BR Jr, Baker CL 3rd, Bartolozzi AR, Baumgarten KM, Bechler JR, Berg JH, Bernas GA, Brockmeier SF, Brophy RH, Bush-Joseph CA, Butler JB 5th, Campbell JD, Carey JL, Carpenter JE, Cole BJ, Cooper JM, Cox CL, Creighton RA, Dahm DL, David TS, Flanigan DC, Frederick RW, Ganley TJ, Garofoli EA, Gatt CJ Jr, Gecha SR, Giffin JR, Hame SL, Hannafin JA, Harner CD, Harris NL Jr, Hechtman KS, Hershman EB, Hoellrich RG, Hosea TM, Johnson DC, Johnson TS, Jones MH, Kaeding CC, Kamath GV, Klootwyk TE, Levy BA, Ma CB, Maiers GP 2nd, Marx RG, Matava MJ, Mathien GM, McAllister DR, McCarty EC, McCormack RG, Miller BS, Nissen CW, O'Neill DF, Owens BD, Parker RD, Purnell ML, Ramappa AJ, Rauh MA, Rettig AC, Sekiya JK, Shea KG, Sherman OH, Slauterbeck JR, Smith MV, Spang JT, Svoboda SJ, Taft TN, Tenuta JJ, Tingstad EM, Vidal AF, Viskontas DG, White RA, Williams JS Jr, Wolcott ML, Wolf BR, York JJ.

Am J Sports Med. 2017 Jul;45(9):2068-2076. doi: 10.1177/0363546517707207. Epub 2017 May 30.

PMID:
28557557
14.

Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.

Lee JM, Cimino-Mathews A, Peer CJ, Zimmer A, Lipkowitz S, Annunziata CM, Cao L, Harrell MI, Swisher EM, Houston N, Botesteanu DA, Taube JM, Thompson E, Ogurtsova A, Xu H, Nguyen J, Ho TW, Figg WD, Kohn EC.

J Clin Oncol. 2017 Jul 1;35(19):2193-2202. doi: 10.1200/JCO.2016.72.1340. Epub 2017 May 4.

PMID:
28471727
15.

Comparative analysis of HPV16 gene expression profiles in cervical and in oropharyngeal squamous cell carcinoma.

Cerasuolo A, Annunziata C, Tortora M, Starita N, Stellato G, Greggi S, Maglione MG, Ionna F, Losito S, Botti G, Buonaguro L, Buonaguro FM, Tornesello ML.

Oncotarget. 2017 May 23;8(21):34070-34081. doi: 10.18632/oncotarget.15977.

16.

The clinical trials crisis in gynecologic oncology.

Del Carmen MG, Annunziata CM, Rice LW.

Gynecol Oncol. 2017 Jun;145(3):481-482. doi: 10.1016/j.ygyno.2017.04.003. Epub 2017 Apr 11. No abstract available.

PMID:
28410755
17.

Evidence for a Mesothelial Origin of Body Cavity Effusion Lymphomas.

Sanchez-Martin D, Uldrick TS, Kwak H, Ohnuki H, Polizzotto MN, Annunziata CM, Raffeld M, Wyvill KM, Aleman K, Wang V, Marshall VA, Whitby D, Yarchoan R, Tosato G.

J Natl Cancer Inst. 2017 Sep 1;109(9). doi: 10.1093/jnci/djx016.

PMID:
28376153
18.

An Engineered Cell-Instructive Stroma for the Fabrication of a Novel Full Thickness Human Cervix Equivalent In Vitro.

De Gregorio V, Imparato G, Urciuolo F, Tornesello ML, Annunziata C, Buonaguro FM, Netti PA.

Adv Healthc Mater. 2017 Jun;6(11). doi: 10.1002/adhm.201601199. Epub 2017 Mar 29.

PMID:
28371541
19.

Inhibiting mitochondrial respiration prevents cancer in a mouse model of Li-Fraumeni syndrome.

Wang PY, Li J, Walcott FL, Kang JG, Starost MF, Talagala SL, Zhuang J, Park JH, Huffstutler RD, Bryla CM, Mai PL, Pollak M, Annunziata CM, Savage SA, Fojo AT, Hwang PM.

J Clin Invest. 2017 Jan 3;127(1):132-136. doi: 10.1172/JCI88668. Epub 2016 Nov 21.

20.

Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer.

Lee JM, Peer CJ, Yu M, Amable L, Gordon N, Annunziata CM, Houston N, Goey AK, Sissung TM, Parker B, Minasian L, Chiou VL, Murphy RF, Widemann BC, Figg WD, Kohn EC.

Clin Cancer Res. 2017 Mar 15;23(6):1397-1406. doi: 10.1158/1078-0432.CCR-16-1546. Epub 2016 Sep 23.

21.

Identification of therapeutic targets applicable to clinical strategies in ovarian cancer.

Kim MK, Caplen N, Chakka S, Hernandez L, House C, Pongas G, Jordan E, Annunziata CM.

BMC Cancer. 2016 Aug 24;16:678. doi: 10.1186/s12885-016-2675-5.

22.

SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes FADD and BIRC2.

Eytan DF, Snow GE, Carlson S, Derakhshan A, Saleh A, Schiltz S, Cheng H, Mohan S, Cornelius S, Coupar J, Sowers AL, Hernandez L, Mitchell JB, Annunziata CM, Chen Z, Van Waes C.

Cancer Res. 2016 Sep 15;76(18):5442-5454. doi: 10.1158/0008-5472.CAN-15-3317. Epub 2016 Jul 28.

23.

Molecular Pathways: The Balance between Cancer and the Immune System Challenges the Therapeutic Specificity of Targeting Nuclear Factor-κB Signaling for Cancer Treatment.

Zeligs KP, Neuman MK, Annunziata CM.

Clin Cancer Res. 2016 Sep 1;22(17):4302-8. doi: 10.1158/1078-0432.CCR-15-1374. Epub 2016 Jul 15. Review.

24.

Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma.

Pezzuto F, Izzo F, Buonaguro L, Annunziata C, Tatangelo F, Botti G, Buonaguro FM, Tornesello ML.

Oncotarget. 2016 Aug 23;7(34):54253-54262. doi: 10.18632/oncotarget.9801.

25.

Characterization of ovarian cancer cell lines as in vivo models for preclinical studies.

Hernandez L, Kim MK, Lyle LT, Bunch KP, House CD, Ning F, Noonan AM, Annunziata CM.

Gynecol Oncol. 2016 Aug;142(2):332-40. doi: 10.1016/j.ygyno.2016.05.028. Epub 2016 May 28.

26.

Detection of human papillomavirus DNA in peri-tumor tissues and pelvic lymph nodes as potential molecular marker of micrometastasis in cervical cancer.

Tortora M, Annunziata C, Liguori G, Losito S, Botti G, Greggi S, Buonaguro L, Buonaguro FM, Tornesello ML.

Infect Agent Cancer. 2016 May 11;11:22. doi: 10.1186/s13027-016-0068-7. eCollection 2016.

27.

Editorial: Inhibiting PARP as a Strategic Target in Cancer.

Zorn KK, Annunziata CM.

Front Oncol. 2016 Apr 15;6:91. doi: 10.3389/fonc.2016.00091. eCollection 2016. No abstract available.

28.

Monocyte and interferon based therapy for the treatment of ovarian cancer.

Green DS, Nunes AT, Annunziata CM, Zoon KC.

Cytokine Growth Factor Rev. 2016 Jun;29:109-15. doi: 10.1016/j.cytogfr.2016.02.006. Epub 2016 Mar 15.

29.

Candidate Soluble Immune Mediators in Young Women with High-Risk Human Papillomavirus Infection: High Expression of Chemokines Promoting Angiogenesis and Cell Proliferation.

Zanotta N, Tornesello ML, Annunziata C, Stellato G, Buonaguro FM, Comar M.

PLoS One. 2016 Mar 18;11(3):e0151851. doi: 10.1371/journal.pone.0151851. eCollection 2016.

30.

Caspase 8 expression may determine the survival of women with ovarian cancer.

Kim M, Hernandez L, Annunziata CM.

Cell Death Dis. 2016 Jan 14;7:e2045. doi: 10.1038/cddis.2015.398. No abstract available.

31.

A dual role for Caspase8 and NF-κB interactions in regulating apoptosis and necroptosis of ovarian cancer, with correlation to patient survival.

Hernandez L, Kim MK, Noonan AM, Sagher E, Kohlhammer H, Wright G, Lyle LT, Steeg PS, Anver M, Bowtell DD; Australian Ovarian Cancer Study Group 57, Annunziata CM.

Cell Death Discov. 2015 Dec 14;1:15053. doi: 10.1038/cddiscovery.2015.53. eCollection 2015.

32.

Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer.

Noonan AM, Bunch KP, Chen JQ, Herrmann MA, Lee JM, Kohn EC, O'Sullivan CC, Jordan E, Houston N, Takebe N, Kinders RJ, Cao L, Peer CJ, Figg WD, Annunziata CM.

Cancer. 2016 Feb 15;122(4):588-597. doi: 10.1002/cncr.29783. Epub 2015 Nov 13.

33.

Identification of Human Herpesvirus 8 Sequences in Conjunctiva Intraepithelial Neoplasia and Squamous Cell Carcinoma of Ugandan Patients.

Starita N, Annunziata C, Waddell KM, Buonaguro L, Buonaguro FM, Tornesello ML.

Biomed Res Int. 2015;2015:801353. doi: 10.1155/2015/801353. Epub 2015 Oct 5. Review.

34.

A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma.

Holkova B, Zingone A, Kmieciak M, Bose P, Badros AZ, Voorhees PM, Baz R, Korde N, Lin HY, Chen JQ, Herrmann M, Xi L, Raffeld M, Zhao X, Wan W, Tombes MB, Shrader E, Weir-Wiggins C, Sankala H, Hogan KT, Doyle A, Annunziata CM, Wellons M, Roberts JD, Sullivan D, Landgren O, Grant S.

Clin Cancer Res. 2016 Mar 1;22(5):1067-75. doi: 10.1158/1078-0432.CCR-15-1076. Epub 2015 Oct 7.

35.

The role of reproductive hormones in epithelial ovarian carcinogenesis.

Gharwan H, Bunch KP, Annunziata CM.

Endocr Relat Cancer. 2015 Dec;22(6):R339-63. doi: 10.1530/ERC-14-0550. Epub 2015 Sep 15. Review.

36.

Are beta-blockers on the therapeutic horizon for ovarian cancer treatment?

Bunch KP, Annunziata CM.

Cancer. 2015 Oct 1;121(19):3380-3. doi: 10.1002/cncr.29394. Epub 2015 Aug 24. No abstract available.

37.

Voltage-gated Na+ Channel Activity Increases Colon Cancer Transcriptional Activity and Invasion Via Persistent MAPK Signaling.

House CD, Wang BD, Ceniccola K, Williams R, Simaan M, Olender J, Patel V, Baptista-Hon DT, Annunziata CM, Gutkind JS, Hales TG, Lee NH.

Sci Rep. 2015 Jun 22;5:11541. doi: 10.1038/srep11541.

38.

Update on Head and Neck Cancer: Current Knowledge on Epidemiology, Risk Factors, Molecular Features and Novel Therapies.

Pezzuto F, Buonaguro L, Caponigro F, Ionna F, Starita N, Annunziata C, Buonaguro FM, Tornesello ML.

Oncology. 2015;89(3):125-36. doi: 10.1159/000381717. Epub 2015 May 8. Review.

PMID:
25967534
39.

Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells.

Kim MK, James J, Annunziata CM.

BMC Cancer. 2015 Mar 28;15:196. doi: 10.1186/s12885-015-1231-z.

40.

In vitro enrichment of ovarian cancer tumor-initiating cells.

House CD, Hernandez L, Annunziata CM.

J Vis Exp. 2015 Feb 18;(96). doi: 10.3791/52446.

41.
42.

The small molecule NSC676914A is cytotoxic and differentially affects NFκB signaling in ovarian cancer cells and HEK293 cells.

Sagher E, Hernandez L, Heywood C, Pauly GT, Young MR, Schneider J, Colburn NH, Annunziata CM.

Cancer Cell Int. 2014 Aug 12;14:75. doi: 10.1186/s12935-014-0075-y. eCollection 2014.

43.

TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix.

Tornesello ML, Annunziata C, Buonaguro L, Losito S, Greggi S, Buonaguro FM.

J Transl Med. 2014 Sep 16;12:255. doi: 10.1186/s12967-014-0255-5.

44.

Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.

Lee JM, Hays JL, Annunziata CM, Noonan AM, Minasian L, Zujewski JA, Yu M, Gordon N, Ji J, Sissung TM, Figg WD, Azad N, Wood BJ, Doroshow J, Kohn EC.

J Natl Cancer Inst. 2014 May 19;106(6):dju089. doi: 10.1093/jnci/dju089. Print 2014 Jun.

45.

Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer.

Szabova L, Bupp S, Kamal M, Householder DB, Hernandez L, Schlomer JJ, Baran ML, Yi M, Stephens RM, Annunziata CM, Martin PL, Van Dyke TA, Weaver Ohler Z, Difilippantonio S.

PLoS One. 2014 Apr 18;9(4):e95649. doi: 10.1371/journal.pone.0095649. eCollection 2014.

46.

A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety.

Hays JL, Kim G, Walker A, Annunziata CM, Lee JM, Squires J, Houston N, Steinberg SM, Kohn EC.

Mol Clin Oncol. 2013 May;1(3):565-569. Epub 2013 Mar 20.

47.

Recent technological advances in using mouse models to study ovarian cancer.

House CD, Hernandez L, Annunziata CM.

Front Oncol. 2014 Feb 13;4:26. doi: 10.3389/fonc.2014.00026. eCollection 2014. Review.

48.

Novel facts about FAK: new connections to drug resistance?

Annunziata CM, Kohn EC.

J Natl Cancer Inst. 2013 Oct 2;105(19):1430-1. doi: 10.1093/jnci/djt255. Epub 2013 Sep 23. No abstract available.

PMID:
24062526
49.

Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions.

Moon DH, Lee JM, Noonan AM, Annunziata CM, Minasian L, Houston N, Hays JL, Kohn EC.

Br J Cancer. 2013 Aug 20;109(4):1072-8. doi: 10.1038/bjc.2013.389. Epub 2013 Jul 18.

50.

Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort.

Azad N, Yu M, Davidson B, Choyke P, Chen CC, Wood BJ, Venkatesan A, Henning R, Calvo K, Minasian L, Edelman DC, Meltzer P, Steinberg SM, Annunziata CM, Kohn EC.

Mol Cell Proteomics. 2013 Jun;12(6):1621-31. doi: 10.1074/mcp.M112.026427. Epub 2013 Feb 28.

Supplemental Content

Loading ...
Support Center